CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

214

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
28/07/26	US$0.1388	+7.76%	332
27/07/26	US$0.1288	-.--%	420
22/07/26	US$0.1288	-4.59%	6,898

Real-time OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 15:57:58 03/06/2026 BST			5-day change	1st Jan Change
0.1052 ^USD	-2.09%		-18.25%	-87.61%

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	2.85M 2.51M 2.34M 2.15M 4.02M 273M 4.12M 27.75M 10.85M 135M 10.71M 10.48M 467M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	24.71M 21.71M 20.26M 18.6M 34.81M 2.37B 35.67M 240M 93.98M 1.17B 92.76M 90.75M 4.05B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.62%	Yield 2024 *	-	Yield 2025	-

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-14	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-20	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-20	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

1 day	-2.09%
1 week	-18.25%
Current month	-38.06%
1 month	-14.39%
3 months	-25.85%
6 months	-89.36%
Current year	-87.61%

CASI Pharmaceuticals, Inc. Share Price

Stocks

CASIF

KYG1933S1012

Pharmaceuticals

Valuation: CASI Pharmaceuticals, Inc.

Chart: CASI Pharmaceuticals, Inc.

Latest news : CASI Pharmaceuticals, Inc.

Press Releases: CASI Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: CASI Pharmaceuticals, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 week	0.11	0.14
1 month	0.11	0.25
Current year	0.05	1.2
1 year	0.05	3.09
3 years	0.05	8.48
5 years	0.05	17.4
10 years	0.05	88.92

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	20/07/2025
Kun Qian DFI	Director of Finance/CFO	44	15/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	31/12/2016

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	31/03/2013
Zhen Bo Su BRD	Director/Board Member	50	20/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	20/03/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
18/03/26	Yue Wu	Other	Director	139,310	0.8992%
18/03/26	Wei Wu He	Other	Director	2,550,550	16.4629%
18/03/26	Hai Huang	Other	Global Chief Commercial Ofcr	280,000	1.8073%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CASI PHARMACEUTICALS, INC.	-2.09%	-18.25%	-93.07%	-95.74%	2.85M
ELI LILLY AND COMPANY	-0.87%	+4.04%	+58.60%	+163.92%	1,079B
JOHNSON & JOHNSON	-0.45%	+3.87%	+57.95%	+52.18%	640B
ABBVIE INC.	+0.04%	+3.95%	+37.69%	+74.54%	465B
ROCHE HOLDING AG	-0.41%	+2.66%	+38.21%	+32.59%	353B
NOVARTIS AG	-0.28%	+1.10%	+35.82%	+41.72%	301B
ASTRAZENECA PLC	-0.50%	+2.54%	+13.15%	+16.31%	271B
NOVO NORDISK A/S	-0.47%	+4.98%	+3.46%	-38.43%	228B
AMGEN INC.	-1.39%	+5.90%	+27.70%	+64.00%	209B
GILEAD SCIENCES, INC.	-1.18%	+1.83%	+16.20%	+72.69%	165B
Average	-0.79%	+4.35%	+19.57%	+38.38%	370.97B
Weighted average by Cap.	-0.61%	+4.86%	+41.76%	+78.18%

	2024	2025
Net sales	28.54M 25.08M 23.41M 21.48M 40.21M 2.73B 41.2M 278M 109M 1.35B 107M 105M 4.68B	20.71M 18.2M 16.99M 15.59M 29.18M 1.98B 29.9M 201M 78.78M 982M 77.76M 76.08M 3.39B
Net income	-39.26M -34.5M -32.2M -29.55M -55.32M -3.76B -56.68M -382M -149M -1.86B -147M -144M -6.43B	-48.06M -42.23M -39.42M -36.17M -67.72M -4.6B -69.39M -467M -183M -2.28B -180M -177M -7.87B
Net Debt	6.05M 5.32M 4.96M 4.55M 8.52M 579M 8.73M 58.84M 23.01M 287M 22.71M 22.22M 991M	21.85M 19.2M 17.92M 16.45M 30.79M 2.09B 31.55M 213M 83.12M 1.04B 82.05M 80.27M 3.58B